205 related articles for article (PubMed ID: 24851084)
1. Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells.
Suzuki S; Tanigawara Y
Proteome Sci; 2014; 12():26. PubMed ID: 24851084
[TBL] [Abstract][Full Text] [Related]
2. S100A10 protein expression is associated with oxaliplatin sensitivity in human colorectal cancer cells.
Suzuki S; Yamayoshi Y; Nishimuta A; Tanigawara Y
Proteome Sci; 2011 Dec; 9():76. PubMed ID: 22206547
[TBL] [Abstract][Full Text] [Related]
3. miR-200b-3p mitigates oxaliplatin resistance via targeting TUBB3 in colorectal cancer.
Wu YZ; Lin HY; Zhang Y; Chen WF
J Gene Med; 2020 Jul; 22(7):e3178. PubMed ID: 32092782
[TBL] [Abstract][Full Text] [Related]
4. miR-124 Intensified Oxaliplatin-Based Chemotherapy by Targeting CAPN2 in Colorectal Cancer.
Xie XQ; Wang MJ; Li Y; Lei LP; Wang N; Lv ZY; Chen KL; Zhou B; Ping J; Zhou ZG; Sun XF
Mol Ther Oncolytics; 2020 Jun; 17():320-331. PubMed ID: 32382656
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylated and downregulated MEIS2 are involved in stemness properties and oxaliplatin-based chemotherapy resistance of colorectal cancer.
Wang X; Ghareeb WM; Zhang Y; Yu Q; Lu X; Huang Y; Huang S; Sun Y; Chi P
J Cell Physiol; 2019 Aug; 234(10):18180-18191. PubMed ID: 30859572
[TBL] [Abstract][Full Text] [Related]
6. The Effect of Compound
Yin W; Zhong G; Fan H; Xia H
Evid Based Complement Alternat Med; 2019; 2019():7564232. PubMed ID: 31949471
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of DNA-binding protein A enhances the chemotherapy sensitivity of colorectal cancer via suppressing the Wnt/β-catenin/Chk1 pathway.
Tong C; Qu K; Wang G; Liu R; Duan B; Wang X; Liu C
Cell Biol Int; 2020 Oct; 44(10):2075-2085. PubMed ID: 32652867
[TBL] [Abstract][Full Text] [Related]
8. [MiR-145 inhibits drug resistance to Oxaliplatin in colorectal cancer cells through regulating G protein coupled receptor 98].
Fu Q; Cheng J; Zhang J; Zhang Y; Chen X; Xie J; Luo S
Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):566-570. PubMed ID: 28534337
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of ADAM17 inhibits cell proliferation and increases oxaliplatin sensitivity in HCT-8 colorectal cancer through EGFR-PI3K-AKT activation.
Zhang Q; Wang C; Han X; Yang G; Ge Z; Zhang G
Biochem Biophys Res Commun; 2018 Sep; 503(4):2333-2339. PubMed ID: 29964008
[TBL] [Abstract][Full Text] [Related]
10. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study.
Hegewisch-Becker S; Gruber Y; Corovic A; Pichlmeier U; Atanackovic D; Nierhaus A; Hossfeld DK
Ann Oncol; 2002 Aug; 13(8):1197-204. PubMed ID: 12181242
[TBL] [Abstract][Full Text] [Related]
11. Cyr61 mediates oxaliplatin resistance in colorectal cancer cells by regulating Bcl-xL expression.
Song Y; Kang Y; Lin Z; Zeng M; Shi P; Lin J; Lu P; Luo L; Cao Y; Zhu X
J Cancer; 2021; 12(7):1952-1959. PubMed ID: 33753993
[TBL] [Abstract][Full Text] [Related]
12. Perifosine enhances the potential antitumor effect of 5-fluorourasil and oxaliplatin in colon cancer cells harboring the PIK3CA mutation.
Morii Y; Tsubaki M; Takeda T; Otubo R; Seki S; Yamatomo Y; Imano M; Satou T; Shimomura K; Nishida S
Eur J Pharmacol; 2021 May; 898():173957. PubMed ID: 33662352
[TBL] [Abstract][Full Text] [Related]
13. miR-33a-5p in small extracellular vesicles as non-invasive biomarker for oxaliplatin sensitivity in human colorectal cancer cells.
Tanaka S; Hosokawa M; Miyamoto T; Nakagawa A; Haruna M; Ueda K; Iwakawa S; Ogawara KI
Biochem Biophys Rep; 2021 Jul; 26():100996. PubMed ID: 33898768
[TBL] [Abstract][Full Text] [Related]
14. Effect of intact oxaliplatin in plasma on a cold allodynia after multiple administrations in colorectal cancer model rats.
Ito Y; Kobuchi S; Takeda M; Morimoto M
Ann Palliat Med; 2020 Sep; 9(5):3000-3006. PubMed ID: 32692214
[TBL] [Abstract][Full Text] [Related]
15. Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil.
Liu A; Qiao J; He L; Liu Z; Chen J; Pei F; Du Y
Onco Targets Ther; 2019; 12():8637-8644. PubMed ID: 31695423
[TBL] [Abstract][Full Text] [Related]
16. RNA interference-mediated silencing of the S100A10 gene attenuates plasmin generation and invasiveness of Colo 222 colorectal cancer cells.
Zhang L; Fogg DK; Waisman DM
J Biol Chem; 2004 Jan; 279(3):2053-62. PubMed ID: 14570893
[TBL] [Abstract][Full Text] [Related]
17. Overexpressed CES2 has prognostic value in CRC and knockdown CES2 reverses L-OHP-resistance in CRC cells by inhibition of the PI3K signaling pathway.
Zhang Y; Sun L; Sun Y; Chen Y; Wang X; Xu M; Chi P; Xu Z; Lu X
Exp Cell Res; 2020 Apr; 389(1):111856. PubMed ID: 31981591
[TBL] [Abstract][Full Text] [Related]
18. Leucovorin and fluorouracil plus oxaliplatin or leucovorin and fluorouracil plus irinotecan as individualized first-line therapy based on a drug sensitivity test.
Ochiai T; Nishimura K; Watanabe T; Kitajima M; Hashiguchi T; Nakatani A; Marusasa T; Muraki A; Nagaoka I; Futagawa S
Exp Ther Med; 2010 Mar; 1(2):325-329. PubMed ID: 22993545
[TBL] [Abstract][Full Text] [Related]
19. Combined chemotherapy of hydroxycampothecin with oxaliplatin as an adjuvant treatment for human colorectal cancer.
Yao Y; Zhao H; Sun Y; Lin F; Tang L; Chen P
Tohoku J Exp Med; 2008 Jul; 215(3):267-78. PubMed ID: 18648187
[TBL] [Abstract][Full Text] [Related]
20. Suppression of GRP78 sensitizes human colorectal cancer cells to oxaliplatin by downregulation of CD24.
Xi J; Chen Y; Huang S; Cui F; Wang X
Oncol Lett; 2018 Jun; 15(6):9861-9867. PubMed ID: 29805687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
